Registration is now closed. Please contact Alicia@onenucleus.com to be added to the waitlist.

The webinar will discuss the ATMP sector, why it is exciting from a technical point of view and what opportunities there are to utilise new and innovative regulatory pathways to get these medicinal products to market, whilst ensuring that the desire for innovation is balanced with the requirement for a robust commercial strategy.

Our webinar will also explore how such critical path thinking impacts investment decisions and is factored into deal structure.

Programme:
14:00 Welcome from One Nucleus
Alicia Gailliez, One Nucleus
14:05 Regulatory routes for value inflection points
Kate Coleman, Director/Principal Consultant, PharmaLex
14:30 Discussion: How does the regulatory regime for cell and gene therapies impact investment decisions?
Julian Hitchcock, Of Counsel, Bristows LLP
Dominic Schmidt, Partner, Syncona
14:50 Q&A
15:00 Close

Registration is free and open to all.